| Literature DB >> 35590089 |
Taiichi Wakiya1, Keinosuke Ishido2, Norihisa Kimura2, Hayato Nagase2, Taishu Kanda2, Sotaro Ichiyama3, Kenji Soma3, Masashi Matsuzaka4, Yoshihiro Sasaki4, Shunsuke Kubota2, Hiroaki Fujita2, Takeyuki Sawano5, Yutaka Umehara5, Yusuke Wakasa6, Yoshikazu Toyoki6, Kenichi Hakamada2.
Abstract
Preoperatively accurate evaluation of risk for early postoperative recurrence contributes to maximizing the therapeutic success for intrahepatic cholangiocarcinoma (iCCA) patients. This study aimed to investigate the potential of deep learning (DL) algorithms for predicting postoperative early recurrence through the use of preoperative images. We collected the dataset, including preoperative plain computed tomography (CT) images, from 41 patients undergoing curative surgery for iCCA at multiple institutions. We built a CT patch-based predictive model using a residual convolutional neural network and used fivefold cross-validation. The prediction accuracy of the model was analyzed. We defined early recurrence as recurrence within a year after surgical resection. Of the 41 patients, early recurrence was observed in 20 (48.8%). A total of 71,081 patches were extracted from the entire segmented tumor area of each patient. The average accuracy of the ResNet model for predicting early recurrence was 98.2% for the training dataset. In the validation dataset, the average sensitivity, specificity, and accuracy were 97.8%, 94.0%, and 96.5%, respectively. Furthermore, the area under the receiver operating characteristic curve was 0.994. Our CT-based DL model exhibited high predictive performance in projecting postoperative early recurrence, proposing a novel insight into iCCA management.Entities:
Mesh:
Year: 2022 PMID: 35590089 PMCID: PMC9120508 DOI: 10.1038/s41598-022-12604-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1The study workflow and methodological process.
Comparison of the perioperative characteristics of the non-early recurrence and early recurrence groups.
| All cases (n = 41) | Non-early recurrence (n = 21) | Early recurrence (n = 20) | ||
|---|---|---|---|---|
| 0.879 | ||||
| Male, n | 20 (48.8) | 10 (47.6) | 10 (50.0) | |
| Female, n | 21 (51.2) | 11 (52.4) | 10 (50.0) | |
| Age, year | 69 (39–81) | 72 (39–81) | 68 (46–81) | 0.388 |
| Body height, cm | 157.0 (133.0–178.0) | 157.5 (133.0–177.0) | 156.0 (140.5–178.0) | 0.814 |
| Body weight, kg | 54.0 (34.0–81.6) | 53.0 (34.0–81.6) | 54.0 (38.9–73.5) | 0.629 |
| Body mass index, kg/m2 | 21.9 (16.6–29.3) | 22.1 (17.0–29.3) | 21.6 (16.6–27.4) | 0.506 |
| 0.232 | ||||
| A, n | 39 (95.1) | 21 (100) | 18 (9.0) | |
| B, n | 2 (4.9) | 0 | 2 (10.0) | |
| C, n | 0 | 0 | 0 | |
| CA19-9, U/mL | 152.0 (3.8–80,355.0) | 128.6 (5.0–3120.0) | 314.0 (3.8–80,355.0) | 0.371 |
| CEA, ng/mL | 3.5 (0.5–61.6) | 2.6 (0.5–43.1) | 3.7 (0.5–61.6) | 0.438 |
| 0.570 | ||||
| Right hepatectomy, n | 12 (29.3) | 5 (23.8) | 7 (35.0) | |
| Left hepatectomy, n | 18 (43.9) | 9 (42.9) | 9 (45.0) | |
| Right anterior sectionectomy, n | 3 (7.3) | 2 (9.5) | 1 (5.0) | |
| Right posterior sectionectomy, n | 1 (2.4) | 0 | 1 (5.0) | |
| Partial resection, n | 7 (17.1) | 5 (23.8) | 2 (10.0) | |
| Lymph node dissection, n | 11 (26.8) | 5 (23.8) | 8 (40.0) | 0.266 |
| Tumor size, mm | 50.0 (16.0–150.0) | 50.0 (16.0–150.0) | 55.0 (25.0–150.0) | 0.347 |
| Solitary tumor, n | 28 (68.3) | 17 (81.0) | 11 (55.0) | 0.074 |
| T category, n | 0.703 | |||
| T1a | 6 (14.6) | 2 (9.5) | 4 (20.0) | |
| T1b | 3 (7.3) | 2 (9.5) | 1 (5.0) | |
| T2 | 24 (58.5) | 14 (66.7) | 10 (50.0) | |
| T3 | 5 (12.2) | 2 (9.5) | 3 (15.0) | |
| T4 | 3 (7.3) | 1 (4.8) | 2 (10.0) | |
| N category, n | 0.002 | |||
| N0 | 28 (68.3) | 19 (90.5) | 9 (45.0) | |
| N1 | 13 (31.7) | 2 (9.5) | 11 (55.0) | |
| M category, n | 1.000 | |||
| M0 | 41 (100) | 21 (100) | 20 (100) | |
| TNM Stage, n | 0.055 | |||
| IA | 3 (7.3) | 2 (9.5) | 1 (5.0) | |
| IB | 3 (7.3) | 2 (9.5) | 1 (5.0) | |
| II | 17 (41.5) | 12 (57.1) | 5 (25.0) | |
| IIIA | 3 (7.3) | 2 (9.5) | 1 (5.0) | |
| IIIB | 15 (36.6) | 3 (14.3) | 12 (60.0) | |
| IV | 0 | 0 | 0 | |
| Intrahepatic metastasis, n | 12 (29.3) | 4 (19.0) | 8 (40.0) | 0.141 |
| Positive surgical margin, n | 3 (7.3) | 2 (9.5) | 1 (5.0) | > 0.999 |
CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, UICC union for international cancer control.
Figure 2The receiver operating characteristics curves of logistic regression analysis and the DL model. ROC curves show the performance of logistic regression analysis and the ResNet model in the validation dataset in detecting early recurrence. The AUC of logistic regression analysis is 0.770, and the average AUC of the convolutional neural network (CNN) model is 0.994.
Performance of the DL model in the training data set.
| Fold 1 | Fold 2 | Fold 3 | Fold 4 | Fold 5 | Average | SD | |
|---|---|---|---|---|---|---|---|
| Sensitivity, % | 99.0 | 98.5 | 99.0 | 99.6 | 98.4 | 98.9 | 0.5 |
| Specificity, % | 94.4 | 97.9 | 96.6 | 99.1 | 97.1 | 97.0 | 1.7 |
| False negative rate, % | 1.0 | 1.5 | 1.0 | 0.4 | 1.6 | 1.1 | 0.5 |
| False positive rate, % | 5.6 | 2.1 | 3.4 | 0.9 | 2.9 | 3.0 | 1.7 |
| Positive predictive value, % | 96.9 | 98.8 | 98.1 | 99.5 | 98.4 | 98.3 | 1.0 |
| Negative predictive value, % | 98.1 | 97.5 | 98.2 | 99.3 | 97.1 | 98.0 | 0.9 |
| Accuracy, % | 97.3 | 98.3 | 98.1 | 99.4 | 97.9 | 98.2 | 0.8 |
| AUC | 0.997 | 0.999 | 0.998 | 1.000 | 0.998 | 0.998 | 0.1 |
AUC the area under the receiver operating characteristic curve, SD standard deviation.
Performance of the DL model in the validation data set.
| Fold 1 | Fold 2 | Fold 3 | Fold 4 | Fold 5 | Average | SD | |
|---|---|---|---|---|---|---|---|
| Sensitivity, % | 97.9 | 97.6 | 97.8 | 98.4 | 97.5 | 97.8 | 0.3 |
| Specificity, % | 90.6 | 95.9 | 92.5 | 96.6 | 94.6 | 94.0 | 2.5 |
| False negative rate, % | 2.1 | 2.4 | 2.2 | 1.6 | 2.5 | 2.2 | 0.3 |
| False positive rate, % | 9.4 | 4.1 | 7.5 | 3.4 | 5.4 | 6.0 | 2.5 |
| Positive predictive value, % | 94.8 | 97.7 | 95.8 | 98.1 | 96.9 | 96.7 | 1.3 |
| Negative predictive value, % | 96.2 | 95.8 | 95.9 | 97.1 | 95.5 | 96.1 | 0.6 |
| Accuracy, % | 95.3 | 97.0 | 95.9 | 97.7 | 96.4 | 96.5 | 1.0 |
| AUC | 0.990 | 0.996 | 0.993 | 0.998 | 0.994 | 0.994 | 0.3 |
AUC the area under the receiver operating characteristic curve, SD standard deviation.
Figure 3A heatmap of iCCA on a preoperative plain CT using our prediction model. The color bar illustrates the degree of probability the model paid to it. Red areas represent a high risk of early recurrence; blue areas represent a low risk of early recurrence. (A) original image of a non-early recurrence case; (B) original image of an early recurrence case; (C) heatmap of a non-early recurrence case; (D) heatmap of an early recurrence case.
Comparison of perioperative characteristics depending on prediction accuracy.
| Under 25% (n = 11) | Over 25% (n = 30) | ||
|---|---|---|---|
| 0.159 | |||
| Male, n | 3 (27.3) | 17 (56.7) | |
| Female, n | 8 (72.7) | 13 (43.3) | |
| Age, year | 68 (60–77) | 70 (39–81) | 0.755 |
| Body height, cm | 154.0 (133.0–173.5) | 158.5 (140.5–178.0) | 0.333 |
| Body weight, kg | 51.0 (34.0–73.5) | 55.3 (38.0–81.6) | 0.547 |
| Body mass index, kg/m2 | 22.1 (19.2–26.0) | 21.7 (16.6–29.3) | 0.937 |
| 0.380 | |||
| A, n | 11 (100) | 28 (93.3) | |
| B, n | 0 | 2 (6.7) | |
| C, n | 0 | 0 | |
| CA19-9, U/mL | 39.1 (5.0–3120.0) | 179.0 (3.8–80,355.0) | 0.526 |
| CEA, ng/mL | 4.1 (0.5–43.1) | 3.0 (0.5–61.6) | 0.706 |
| 0.661 | |||
| Right hepatectomy, n | 3 (27.3) | 9 (30.0) | |
| Left hepatectomy, n | 5 (45.5) | 13 (43.3) | |
| Right anterior sectionectomy, n | 0 | 3 (10.0) | |
| Right posterior sectionectomy, n | 0 | 1 (3.3) | |
| Partial resection, n | 3 (27.3) | 4 (13.3) | |
| Lymph node dissection, n | 4 (36.4) | 9 (30.0) | 0.698 |
| Tumor size, mm | 42.0 (16.0–60.0) | 57.5 (17.0–150.0) | 0.025 |
| Solitary tumor, n | 8 (72.7) | 20 (66.7) | > 0.999 |
| T category, n | 0.482 | ||
| T1a | 1 (9.1) | 5 (16.7) | |
| T1b | 0 | 3 (10.0) | |
| T2 | 8 (72.7) | 16 (53.3) | |
| T3 | 2 (18.2) | 3 (10.0) | |
| T4 | 0 | 3 (10.0) | |
| N category, n | > 0.999 | ||
| N0 | 8 (72.7) | 20 (66.7) | |
| N1 | 3 (27.3) | 10 (33.3) | |
| M category, n | 1.000 | ||
| M0 | 11 (100) | 30 (100) | |
| TNM Stage, n | 0.406 | ||
| IA | 1 (9.1) | 2 (6.7) | |
| IB | 0 | 3 (10.0) | |
| II | 5 (45.5) | 12 (40.0) | |
| IIIA | 2 (18.2) | 1 (3.3) | |
| IIIB | 3 (27.3) | 12 (40.0) | |
| IV | 0 | 0 | |
| Intrahepatic metastasis, n | 3 (27.3) | 9 (30.0) | > 0.999 |
| Positive surgical margin, n | 1 (9.1) | 2 (6.7) | > 0.999 |
| Early recurrence, n | 4 (36.4) | 16 (53.3) | 0.484 |
| Prediction accuracy, % | 95.4 (85.6–96.0) | 98.4 (96.2–100) | < 0.001 |
CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, UICC union for international cancer control.